Philogen Spa is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	6.23
Equity-to-Asset	0.76
Debt-to-Equity	0.13
Debt-to-EBITDA	-6.07
Piotroski F-Score	3/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	17.94	Distress Grey Safe
Beneish M-Score	-2.31	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	63.7
	3-Year EBITDA Growth Rate	44.2
	3-Year EPS without NRI Growth Rate	16.2
	3-Year FCF Growth Rate	16.7
	3-Year Book Growth Rate	17.9

Momentum Rank

6/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	66.18
	9-Day RSI	60.45
	14-Day RSI	58.48
	6-1 Month Momentum %	14.77
	12-1 Month Momentum %	26.65

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	7.02
	Quick Ratio	6.84
	Cash Ratio	5.93
	Days Inventory	46.71
	Days Sales Outstanding	16.93
	Days Payable	154.12

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	0.3
	Shareholder Yield %	0.28

Profitability Rank

	Name	Current	Vs Industry		Vs History
	Gross Margin %	24.51
	Operating Margin %	-36.16
	Net Margin %	-26.64
	FCF Margin %	-46.21
	ROE %	-6.3
	ROA %	-4.86
	ROIC %	-26.07
	ROC (Joel Greenblatt) %	-23.56
	ROCE %	-4.93

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	35.78
	PB Ratio	9.12
	Price-to-Tangible-Book	9.41
	EV-to-EBIT	-138.23
	EV-to-EBITDA	-390.78
	EV-to-Revenue	33.67
	EV-to-FCF	-71.36
	Price-to-Net-Current-Asset-Value	13.93
	Price-to-Net-Cash	18.02
	Earnings Yield (Greenblatt) %	-0.72
	FCF Yield %	-1.27

GF Value: €70.4

MIL:PHIL

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with PHIL. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.